Citius Oncology (CTOR) Short term Debt (2021 - 2022)
Citius Oncology (CTOR) recorded quarterly Short term Debt of $193164.0 in Q3 2022, up 47.81% quarter-over-quarter from $130687.0 in Q4 2021.
Citius Oncology (CTOR) Short term Debt (2021 - 2022) Analysis & Trends
Citius Oncology's Short term Debt history runs 2 years deep, the most recent figure standing at $193164.0 for Q3 2022.
- In Q3 2022, Short term Debt changed N/A year-over-year to $193164.0; the TTM figure through Sep 2022 stood at $193164.0 (changed N/A YoY), while the FY2021 annual figure was $130687.0, changed N/A from the prior year.
- Short term Debt was $193164.0 for Q3 2022 at Citius Oncology, up from $130687.0 in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $193164.0 in Q3 2022 to a low of $130687.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Citius Oncology | 75.12 Mn | 72.49 Mn | 1.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 193,164.00 |
| Dec 31, 2021 | 130,687.00 |